Skip to main content

Should I take Aubagio in the morning or night?

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 22, 2023.

Official answer

by Drugs.com

It does not matter if you take Aubagio in the morning or at night, but you should take it at around the same time each day. So if you decide to take your Aubagio in the morning, then take it every morning. If you decide to take it at night, then take it every night. If you experience fatigue, tiredness, or weakness with Aubagio, you may find it better to take it at night.

The recommended dosage of Aubagio is one tablet (either the 7mg strength or 14mg strength) taken once daily with a glass of water. Aubagio may be taken with or without food.

References
  • Aubagio (teriflunomide). Updated 07/2021. Genzyme Corporation https://www.drugs.com/pro/aubagio.html
  • Aubagio (teriflunomide). 2021. https://www.aubagio.com/

Read next

Weight loss is reported as a common side effect of Aubagio, occurring in 1% to 10% of people in post-marketing studies, although it is not listed as a side effect in the product information. Rapid weight gain has also been reported with Aubagio but this is considered uncommon. Continue reading

Aubagio is made by Sanofi Genzyme which is the specialty care business arm of Sanofi. It is unclear where Aubagio is manufactured, as Sanofi has 69 manufacturing sites in 32 countries, but the new digital manufacturing site in Framingham, Ma, USA has been reported to make medicines for Sanofi Genzyme’s specialty care portfolio. Aubagio is a specialty medicine that may be used for the treatment of Multiple Sclerosis. Continue reading

Aubagio is unlikely to reduce fatigue associated with Multiple Sclerosis (MS). 85% of patients with MS report fatigue and 76.6% report that fatigue has a significant impact on their lives. One study found ponesimod to be superior to Aubagio at reducing fatigue as measured by The Fatigue Symptoms and Impacts Questionnaire–Relapsing Multiple Sclerosis which is a patient-reported questionnaire designed to assess fatigue-related symptoms and how they affect people with MS. The investigators found that the fatigue of ponesimod patients stabilized, while that of the Aubagio patients worsened over time. Continue reading

Related medical questions

Drug information

Related support groups

Medical Disclaimer